41 assets in Ovarian Endometrioid Adenocarcinoma

Therapeutic assets addressing Ovarian Endometrioid Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P3	BBB (72)
Olaparib Ovarian Endometrioid Adenocarcinoma	University of Colorado, Denver	P3	BB (70)
Adriamycin Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P3	BB (69)
Cyclophosphamide Ovarian Endometrioid Adenocarcinoma	Roswell Park Cancer Institute	P2	BB (66)
Cis-Diamminedichloroplatinum Ii Ovarian Endometrioid Adenocarcinoma	Genelux Corporation	P3	BB (65)
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine Ovarian Endometrioid Adenocarcinoma	Mayo Clinic	P2	BB (65)
Pembrolizumab Ovarian Endometrioid Adenocarcinoma	Roswell Park Cancer Institute	P2	BB (65)
Cediranib Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P3	BB (64)
Atezolizumab Ovarian Endometrioid Adenocarcinoma	University Health Network, Toronto	P2/3	B (62)
Nogitecan Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2/3	B (62)
Letrozole Ovarian Endometrioid Adenocarcinoma	Swiss GO Trial Group	P3	B (61)
Docetaxel Ovarian Endometrioid Adenocarcinoma	Genelux Corporation	P3	B (60)
Olvimulogene Nanivacirepvec Ovarian Endometrioid Adenocarcinoma	Genelux Corporation	P3	B (60)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter Ovarian Endometrioid Adenocarcinoma	Mayo Clinic	P2	B (58)
Adsorbed Purified Pertussis Vaccine Ovarian Endometrioid Adenocarcinoma	Mayo Clinic	P2	CCC (53)
Anetumab Ravtansine Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Diphtheria Toxoid Ovarian Endometrioid Adenocarcinoma	Mayo Clinic	P2	CCC (53)
Diphtheria Toxoid Adsorbed Ovarian Endometrioid Adenocarcinoma	Mayo Clinic	P2	CCC (53)
Durvalumab Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Fluzoparib Ovarian Endometrioid Adenocarcinoma	Sun Yat-sen University	P2	CCC (53)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cldn6 (Claudin 6, Claudin-6)], Monoclonal Antibody (Ixotatug) Ovarian Endometrioid Adenocarcinoma	TORL Biotherapeutics, LLC	P2	CCC (53)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pegcetacoplan Ovarian Endometrioid Adenocarcinoma	Roswell Park Cancer Institute	P2	CCC (53)
Pegfilgrastim Ovarian Endometrioid Adenocarcinoma	TORL Biotherapeutics, LLC	P2	CCC (53)
Tazemetostat Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tetanus Toxoid Ovarian Endometrioid Adenocarcinoma	Mayo Clinic	P2	CCC (53)
Adavosertib Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Cdx 1140 Ovarian Endometrioid Adenocarcinoma	Roswell Park Cancer Institute	P2	CCC (51)
Copanlisib Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (49)
Berzosertib Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (43)
Bet Bromodomain Inhibitor Zen-3694 Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (43)
Biological Ni-1801 Ovarian Endometrioid Adenocarcinoma	Light Chain Bioscience - Novimmune SA	P1	CC (43)
Cirtuvivint Ovarian Endometrioid Adenocarcinoma	University of Colorado, Denver	P1	CC (43)
Cytokine-Induced Memory-Like Natural Killer Cells Ovarian Endometrioid Adenocarcinoma	Dana-Farber Cancer Institute	P1	CC (43)
Tuvusertib Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (43)
Amt-151 Ovarian Endometrioid Adenocarcinoma	Multitude Therapeutics Inc.	P1	CC (41)
Ipatasertib Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (41)
nxp800 Ovarian Endometrioid Adenocarcinoma	Nuvectis Pharma, Inc.	P1	CC (41)
Sapanisertib Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (41)
Seclidemstat Ovarian Endometrioid Adenocarcinoma	HonorHealth Research Institute	P1	CC (41)
Tolinapant Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P1/2	NR ()